Insider Trading March 9, 2026

Ascent Industries VP Anthony X Pan Buys $45,234 of Stock Amid Recent Share Drop

Two purchases on March 6, 2026 increase Pan's direct holdings as the company confronts weak Q4 2025 results and a sharp share-price pullback

By Priya Menon ACNT
Ascent Industries VP Anthony X Pan Buys $45,234 of Stock Amid Recent Share Drop
ACNT

Anthony X Pan, Vice President of Sales and Business Development at Ascent Industries Co. (ACNT), executed two purchases of common stock on March 6, 2026, totaling $45,234. The trades came as Ascent’s shares fell roughly 25% over the prior week and followed a disappointing fourth-quarter 2025 earnings report that showed a $1 million loss and large revenue shortfall.

Key Points

  • Anthony X Pan bought 3,400 shares of Ascent Industries on March 6, 2026, totaling $45,234.
  • The purchases raise Pan's direct holdings to 20,651 shares while the stock traded near $13.20 after a roughly 25% decline over the prior week.
  • Ascent reported a $1 million loss in Q4 2025 with EPS of -$0.11 and revenue of $18.76 million, missing expectations and contributing to the stock decline.

Transaction details

Anthony X Pan, who serves as Vice President, Sales & Business Development at Ascent Industries Co. (EXCHANGE:ACNT), reported two purchases of the company’s common stock executed on March 6, 2026. The combined value of the buys was $45,234.

In the first transaction Pan acquired 1,900 shares at $13.28 per share, representing $25,232. He followed with a second purchase of 1,500 shares at $13.335 per share, for $20,002. After these transactions, Pan directly holds 20,651 shares of Ascent Industries Co.


Market context and research notes

The insider purchases occurred as Ascent’s stock traded near $13.20, having declined approximately 25% over the prior week. InvestingPro analysis cited in company data notes that management has been aggressively buying back shares, and that the company carries a "FAIR" financial health score. The platform also advertises a comprehensive Pro Research Report available for ACNT and more than 1,400 other U.S. equities for investors seeking additional detail.


Recent financial performance

Ascent Industries reported weak fourth-quarter 2025 results that preceded the recent share-price movement. The company posted a loss of $1 million for the quarter, compared with a profit of nearly $200,000 in the same period a year earlier. Reported earnings per share (EPS) were -$0.11, missing the forecasted $0.16 by a significant margin and yielding a negative surprise of 168.75%.

Revenue for the quarter totaled $18.76 million, falling well short of the expected $48.9 million and representing a shortfall of 61.64%. Those results have contributed to a decline in Ascent Industries’ share value. Investors and analysts are monitoring these developments closely to assess the company’s near-term prospects.


Key takeaways

  • An Ascent Industries executive added 3,400 shares on March 6, 2026, for $45,234 in total purchases.
  • The buys increased Pan's direct ownership to 20,651 shares amid a roughly 25% one-week stock decline.
  • Recent company results for Q4 2025 showed a $1 million loss and revenue that missed expectations by 61.64%, contributing to downward pressure on the stock.

Investor note

The combination of insider purchases, active buyback activity by management, and a weak quarterly report creates a mixed signal for market participants. Market participants seeking deeper financial data can consult the cited Pro Research Report for ACNT and other U.S. listings.

Risks

  • Recent quarterly results show a $1 million loss and a large revenue shortfall, indicating operational and financial pressures that could continue to affect the company's stock performance - impacts equity markets and industrial-company investors.
  • A substantial one-week share-price decline of around 25% suggests elevated market volatility and potential liquidity or sentiment risks for shareholders - impacts small-cap equity investors.
  • Despite insider buying and management buybacks, the company’s FAIR financial health score and missed earnings and revenue forecasts create uncertainty around near-term recovery prospects - impacts investors assessing fundamentals and valuation.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026